A Market Growing Faster Than Its Core
The global chitosan and chitosan derivatives market was valued at USD 18.76 billion in 2025. Contrive Datum Insights projects it will reach USD 21.29 billion in 2026 and USD 58.62 billion by 2034, a compound annual growth rate of 13.5% across the forecast period. The findings appear in the report "Chitosan And Chitosan Derivatives Market Size, Share & Industry Analysis, By Application, Source, Form, Grade, Molecular weight, and Regional Forecast, 2026-2034".
Chitosan is a biopolymer made by deacetylating chitin from crustacean shells, fungal cell walls and other biological sources. Buyers pick a grade and molecular weight to suit the job: flocculation in water treatment, preservation in food and packaging, carriers in agricultural products, or excipients in pharmaceutical and cosmetic formulations.
Pharmaceutical demand is outrunning the rest because the application asks more of the material. Its value climbs from USD 3 billion to USD 12.31 billion, and the same pattern shows up in the supply chain. Pharmaceutical Grade is the fastest grade at 17.17%, while Industrial Grade still leads on 2025 revenue with 39.98%, or USD 7.5 billion. Other fast lines point the same direction: Fungal source grows at 17.99% and Liquid/Solution form at 17.84%, against a Crustacean Shell base that held 81.98% of 2025 revenue at USD 15.38 billion.
The bull case ends 2034 at USD 69.17 billion. It assumes faster approvals for chitosan-based wound care and drug-delivery products, along with fungal capacity that eases the shell-feedstock constraint early. The bear case holds 2034 revenue to USD 48.07 billion, with delayed wastewater enforcement and higher shell costs as its main drags.
Regions and the Counterweight
China is the largest single country market at USD 4.09 billion in 2025, or 21.8% of global revenue. Tighter wastewater discharge rules in Asia Pacific and Europe are the regional change that could pull the bull case forward. The study covers all five regions down to country level.
The largest application line moves more slowly. Water & Wastewater Treatment carries 26% of 2025 revenue at USD 4.88 billion and grows at 12.48%, below the 13.5% market rate. It stays the largest line through 2034, so it keeps setting the volume floor for producers even as pharmaceutical buyers set the pace. Suppliers built around industrial water treatment and those qualified for pharmaceutical work are serving two different customers, and the data shows the second group growing faster.
The study reports every year from 2020 to 2034, with revenue and growth for each line across application, source, form, grade and molecular weight. It also sets out the competitive landscape and documents the method behind each estimate. The report is available as a PDF, with a free sample on request.